Division of Pathology
Giuseppe Viale has not added Biography.
If you are Giuseppe Viale and would like to personalize this page please email our Author Liaison for assistance.
What can the pathologist offer for optimal treatment choice?
Annals of oncology : official journal of the European Society for Medical Oncology Oct, 2010 | Pubmed ID: 20943626
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Annals of oncology : official journal of the European Society for Medical Oncology Oct, 2011 | Pubmed ID: 21335417
Pathological work up of the primary tumor: getting the proper information out of it.
Breast (Edinburgh, Scotland) Oct, 2011 | Pubmed ID: 22015299
The current state of breast cancer classification.
Annals of oncology : official journal of the European Society for Medical Oncology Sep, 2012 | Pubmed ID: 22987963
Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status.
Breast (Edinburgh, Scotland) Apr, 2013 | Pubmed ID: 23352656
Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Breast (Edinburgh, Scotland) Aug, 2013 | Pubmed ID: 24074800
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Annals of oncology : official journal of the European Society for Medical Oncology Apr, 2014 | Pubmed ID: 24667714
Molecular analysis of sentinel lymph nodes and search for molecular signatures of the metastatic potential of breast cancer.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... Jun, 2014 | Pubmed ID: 24835292
A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response.
Breast (Edinburgh, Scotland) Nov, 2015 | Pubmed ID: 26255744
Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting.
Journal of experimental & clinical cancer research : CR Sep, 2015 | Pubmed ID: 26373379
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast cancer research and treatment Nov, 2015 | Pubmed ID: 26493064
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast cancer research and treatment Dec, 2015 | Pubmed ID: 26590813
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Breast cancer research and treatment Feb, 2016 | Pubmed ID: 26820652
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
European journal of cancer (Oxford, England : 1990) Jul, 2017 | Pubmed ID: 28494403
Controversies in treatment selection for patients with equivocal ER and HER2 results.
Breast (Edinburgh, Scotland) Aug, 2017 | Pubmed ID: 28666922
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Breast cancer research and treatment Jan, 2018 | Pubmed ID: 28929359
Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.
Journal of clinical medicine Jan, 2019 | Pubmed ID: 30669267
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
Breast cancer research and treatment Aug, 2019 | Pubmed ID: 31065870
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes.
Breast cancer research and treatment Nov, 2019 | Pubmed ID: 31422497
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Cancers Oct, 2019 | Pubmed ID: 31653094
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease.
Breast (Edinburgh, Scotland) Nov, 2019 | Pubmed ID: 31839160
DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.
NPJ breast cancer , 2020 | Pubmed ID: 32025567
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
JNCI cancer spectrum Dec, 2019 | Pubmed ID: 32337480
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
NPJ breast cancer , 2020 | Pubmed ID: 32436923
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.
Cancer cell May, 2021 | Pubmed ID: 33798472
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
British journal of cancer Jul, 2021 | Pubmed ID: 33828257
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.
The Lancet. Oncology May, 2021 | Pubmed ID: 33845035
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.
NPJ breast cancer May, 2021 | Pubmed ID: 34050190
Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology Oct, 2021 | Pubmed ID: 34172359
Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study.
Frontiers in oncology , 2021 | Pubmed ID: 34504801
Pathology after neoadjuvant treatment - How to assess residual disease.
Breast (Edinburgh, Scotland) Mar, 2022 | Pubmed ID: 34810049
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.
Cells Jul, 2022 | Pubmed ID: 35892583
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
Virchows Archiv : an international journal of pathology Nov, 2022 | Pubmed ID: 35970977
Giuseppina Bonizzi*,1,
Maria Capra*,1,
Cristina Cassi1,
Giulio Taliento1,
Oriana Pala2,
Elham Sajjadi2,3,
Konstantinos Venetis2,3,
Mariia Ivanova2,
Massimo Monturano4,
Giuseppe Renne2,
Lorenzo Zattoni1,3,
Elena Guerini-Rocco2,3,
Giuseppe Viale2,3,
Roberto Orecchia5,
Nicola Fusco1,2,3
1Biobank for Translational and Digital Medicine Unit, IEO, European Institute of Oncology IRCCS,
2Division of Pathology, IEO, European Institute of Oncology IRCCS,
3Department of Oncology and Hemato-Oncology, University of Milan,
4Patient Safety & Risk Management Service, IEO, European Institute of Oncology IRCCS,
5Scientific Directorate, IEO, European Institute of Oncology IRCCS
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유